For more details on this clinical trial, including contact information, please see this trial’s listing on clinicaltrials.gov:
The purpose of this phase I/II study is to define the maximum tolerated dose of 5-AzaC and the effect on grade II-IV GvHD when given after matched unrelated donor transplant (MUD).
Mon, 04/01/2013 to Sun, 05/01/2016
Bone Marrow Disease(s):
myelodysplastic syndromes (MDS)
Drug: Azacitidine Other Names: Vidaza® Ladakamycin 5-AzaC